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OBJECTIVES We tested the hypothesis that risk of ischemic heart disease (IHD) differs as a function of
apolipoprotein E (APOE) genotype in women and men.
BACKGROUND Apolipoprotein E genotype influences lipids and lipoproteins and, therefore, possibly the risk
of IHD.
METHODS We genotyped 9,241 white women and men from the general population and 940 white
women and men with IHD.
RESULTS Test of interaction suggested that APOE genotype may influence risk of IHD differently in
women and men (p 5 0.07). After age adjustment, the odds ratio (OR) for IHD for epsilon32
versus epsilon33 women was 0.57 (95% confidence interval [CI]: 0.35 to 0.94) while
epsilon43 and epsilon44 versus epsilon33 men had ORs of 1.16 (0.96 to 1.41) and 1.58 (1.01
to 2.45). After adjustment for age and other conventional cardiovascular risk factors, the
equivalent ORs were for epsilon32 women 0.38 (0.18 to 0.79), for epsilon43 men 1.35
(1.02–1.78) and for epsilon44 men 1.58 (0.80 to 3.08). Equivalent ORs for epsilon43 and
epsilon44 versus epsilon33 women and for epsilon32 versus epsilon33 men were all close to
1.0 and nonsignificant. Of the total risk of IHD relative to the epsilon33 genotype, the
fraction attributed to epsilon32 in women was 29%, while the fractions attributed to
epsilon43 and epsilon44 in men were 18% and 12%.
CONCLUSIONS Relative to epsilon33 individuals, epsilon32 women are protected while epsilon43 and
epsilon44 men are particularly susceptible to IHD. (J Am Coll Cardiol 2000;35:1192–9) ©
2000 by the American College of Cardiology
The apolipoprotein E (APOE) polymorphism consists of
three alleles (epsilon2, epsilon3 and epsilon4) on the long
arm of chromosome 19 (1–3), coding for three protein
isoforms, APOE-2, APOE-3 and APOE-4. The APOE-2
isoform differs from APOE-3 by a cysteine for arginine
substitution at amino acid residue 158, while APOE-4
differs from APOE-3 by an arginine for cysteine substitu-
tion at residue 112. Apolipoprotein E mediates interaction
with lipoprotein receptors of mainly triglyceride-rich li-
poproteins, the affinity of which depend on the APOE
isoform (1).
Previous studies suggest that effects of the APOE poly-
morphism on lipids and lipoproteins differ in women and
men (4–8). It remains unknown, however, whether effects
of the APOE polymorphism on risk of ischemic heart
disease (IHD) also differ by gender (1,9–12).
We tested the hypothesis that risk of IHD differs as a
function of the six APOE genotypes in women and men.
For this purpose, 9,241 individuals sampled from a white
general population, the Copenhagen City Heart Study, and
940 patients with IHD were genotyped.
METHODS
Subjects. The Copenhagen City Heart Study (third exam-
ination, 1991 through 1994) includes an almost equal
number of women (55%) and men stratified into 10 year age
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groups from 20 to 80 years and above, drawn randomly from
the Copenhagen Central Population Register with the aim
to obtain a representative sample of the Danish general
population (13–19). For this study 9,241 individuals were
genotyped; of these, 557 subjects suffered from IHD
(13,19). Patients with IHD were identified among 992
consecutive patients from the Greater Copenhagen Area
referred for coronary angiography in the period 1991
through 1993 (13,14). All 992 patients were evaluated by
experienced cardiologists at the Department of Cardiology,
Copenhagen University Hospital (Rigshospitalet), and 948
patients (26% women) had IHD (18,20). Of these 948
patients, 940 were genotyped. In both samples about 99%
were white. The study was approved by Danish ethical
committees: no. 100.2039/91 Copenhagen and Frederiks-
berg committee and no. KA 93125 Copenhagen County
committee.
DNA analyses. Apolipoprotein E genotypes were identi-
fied by polymerase chain reaction (PCR) followed by
restriction enzyme digestion of the amplified DNA (244 bp)
with HhaI as previously described (21), except that, due to
the large sample size, we used a 5% agarose gel instead of a
polyacrylamide gel. However, on the agarose gel we could
not always detect the 48 base pair (bp) band that distin-
guished between the epsilon22 and the epsilon32 genotypes;
we, therefore, retyped all epsilon22 and epsilon32 geno-
types, using a second PCR (sense primer: 59ACATGGAG-
GACGTGTGCGG93; antisense primer: 59ACGCGGC-
CCTGTTCCACCA93) followed by digestion of the PCR
product (250 bp) with HaeII (epsilon22 homozygotes: 2 3
187 bp; epsilon32 heterozygotes: 1 3 187 bp, 1 3 152 bp,
1 3 35 bp, and common bands of 32, 18 and 13 bp). The
187 bp band and 152 bp band (epsilon32) were clearly
distinguishable on an agarose gel.
Other analyses. Blood samples were drawn in the fasting
state in patients with IHD but in the nonfasting state in
participants of the Copenhagen City Heart Study. Colori-
metric and turbidimetric assays measured levels of total
cholesterol, high density lipoprotein (HDL) cholesterol,
triglycerides, apoB, apoAI (all Boehringer Mannheim,
Mannheim, Germany) and lipoprotein(a) total mass
(DAKO A/S, Glostrup, Denmark). Height, weight, systolic
and diastolic blood pressure were measured in the Copen-
hagen City Heart Study as described (16). Criteria for
hypertension and diabetes mellitus were those previously
used (13–15,17,18). Body mass index was weight divided by
height2 (kg/m2).
Statistical analyses. A p value ,0.05 was considered
significant. All data were analyzed in each gender separately
using the SPSS program (22). Kruskal-Wallis analysis of
variance compared levels of lipids and lipoproteins as a
function of APOE genotype; two-genotype comparisons
and tests of interaction are reported elsewhere (R. Frikke-
Schmidt et al. 1999, in preparation). Results were similar
when we used a case-referent study design (cases vs. all
individuals sampled from the general population), a case-
control study design (cases vs. individuals from the general
population without IHD) or a pooled case-control study
design (cases plus individuals with IHD from the general
population vs. individuals from the general population
without IHD). We have chosen to present results from the
case-referent study design, as done previously (13,14,17,18).
Results were also similar whether we excluded individuals
taking lipid lowering medication or not and whether we
allowed for use of antihypertensive medication or not. We
have chosen to present results on all individuals without
adjustment for use of these medications. Logistic regression
(23,24) was used to explore the impact of APOE genotype,
hypertension, diabetes mellitus, smoking and tertiles of total
cholesterol, apoB, HDL cholesterol, apoAI and triglycer-
ides on risk of IHD. Lipids and lipoproteins as risk factors
for IHD were evaluated as continuous covariates, in tertiles
or in quartiles; all showed similar results, and for simplicity
we chose to present results based on tertiles. Analysis on
APOE genotype adjusted for
1) age only,
2) age and known cardiovascular risk factors (total choles-
terol, HDL cholesterol, apoAI, triglycerides, lipopro-
tein(a), body mass index, hypertension, diabetes melli-
tus and smoking for both men and women and, in
addition, for menopausal status and use of hormonal
replacement therapy [HRT] in women), or
3) age and apoB levels.
Interaction between APOE genotype and lipid and non-
lipid covariates were explored in logistic regression models
including APOE genotype, the risk factor in question and,
in addition, an interaction term for these two factors.
Population attributable risk was calculated as: f(R 2 1)/(1
1 f[R 2 1]), where f is the frequency of the risk factor in
the population and R is the odds ratio (OR) for IHD (25).
RESULTS
Basic characteristics of participants in this study are given in
Table 1 and genotype frequencies in Table 2. Genotype
frequencies in the sample from the general population did
Abbreviations and Acronyms
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1193JACC Vol. 35, No. 5, 2000 Frikke-Schmidt et al.
April 2000:1192–9 APOE Genotype, Gender and Risk of IHD
not differ significantly from those predicted by the Hardy-
Weinberg equilibrium (chi-square: 0.20 , p , 0.30).
APOE genotype and lipids and lipoproteins. When age
was adjusted for, APOE genotype from epsilon22 to epsi-
lon32 to epsilon42 to epsilon33 to epsilon43 to epsilon44
was associated with a stepwise increase in cholesterol and
apolipoprotein B (apoB) in both genders and a stepwise
decrease in HDL cholesterol in women (Fig. 1). In both
genders epsilon33 individuals had the lowest levels of
nonfasting triglycerides, while the highest levels were found
in individuals with epsilon22 and epsilon44 genotypes. The
results in women were similar when premenopausal women,
untreated postmenopausal women and postmenopausal
women on HRT were examined separately (Fig. 2), except
that HRT seemed to abolish the effect of APOE genotype
on HDL cholesterol and triglycerides in postmenopausal
women. Two-genotype comparisons and tests of interaction
between APOE genotype and conventional cardiovascular
risk factors in predicting these lipid and lipoprotein traits
are reported elsewhere (R. Frikke-Schmidt et al. 1999, in
preparation).
Lipids, lipoproteins and risk of IHD. When age was
adjusted for, risk of IHD disease in both women and men
increased as a function of levels of apoB and triglycerides
and decreased as a function of levels of HDL cholesterol,
while levels of total cholesterol did not confer any major
change in risk (Fig. 3); however, non-HDL cholesterol (i.e.,
mainly low density lipoprotein [LDL] cholesterol) was a
predictor of IHD risk in both genders (data not shown).
When in addition the logistic regression analysis adjusted
for other known cardiovascular risk factors, the results were
similar to those shown in Figure 3 (data not shown).
Table 1. Basic Characteristics of Participants
General Population
Patients With Ischemic Heart
Disease
Women Men Women Men
No. of individuals* 5,112 4,129 247 693
Age (yr) 58 6 0.2 57 6 0.2 57 6 0.6 59 6 0.4
Cholesterol (mmol/L) 6.3 6 0.02 6.0 6 0.02 6.4 6 0.10 6.2 6 0.05
Apolipoprotein B (mg/dL) 86 6 0.3 86 6 0.3 99 6 1.5 97 6 0.8
HDL cholesterol (mmol/L) 1.7 6 0.01 1.4 6 0.01 1.3 6 0.03 1.1 6 0.01
Apolipoprotein AI (mg/dL) 151 6 0.4 130 6 0.4 149 6 1.8 130 6 0.9
Triglycerides (mmol/L)† 1.7 6 0.01 2.1 6 0.03 2.2 6 0.20 2.4 6 0.07
Lipoprotein(a) (mg/dL) 32 6 0.6 29 6 0.6 70 6 4.9 56 6 2.2
Body mass index (kg/m2) 25 6 0.1 26 6 0.1 28 6 1.2 27 6 0.4
Ischemic heart disease (%) 4 9 100 100
Hypertension (%) 19 21 34 29
Diabetes mellitus (%) 2 4 10 10
Smokers (%)‡ 69 82 73 86
Postmenopausal (%) 71 — 79 —
Hormonal replacement
therapy (%)
20 — 9 —
*Number of individuals genotyped; the number for each characteristic varies slightly according to availability of data; †Nonfasting in the general population, but fasting in patients
with IHD; ‡Smokers were ex-smokers and current smokers combined. Values in the upper part of the table are means 6 SEM.
HDL 5 high density lipoprotein.
Table 2. Apolipoprotein E Genotype Frequencies in a Sample From the General Population and in Patients With IHD
Women Men
General Population Patients General Population Patients
n Frequency n Frequency n Frequency n Frequency
epsilon22 28 0.005 2 0.008 20 0.005 5 0.007
epsilon32 655 0.128 18 0.073 513 0.124 68 0.098
epsilon42 127 0.025 8 0.032 117 0.028 18 0.026
epsilon33 2,855 0.558 144 0.583 2,356 0.571 384 0.554
epsilon43 1,298 0.254 67 0.271 1,023 0.248 190 0.274
epsilon44 149 0.029 8 0.032 100 0.024 28 0.040
All 5,112 247 4,129 693
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APOE genotype and risk of IHD. On logistic regression
analysis adjusting for age, female carriers of the epsilon32
genotype versus epsilon33 had an OR for IHD of 0.57 (95%
confidence interval [CI]: 0.35 to 0.94), while no other
genotype conferred altered risk (Fig. 4, women, age-
adjustment). When, in addition, the analysis adjusted for
other known cardiovascular risk factors, including all lipids
and lipoproteins except apoB, female epsilon32 versus
epsilon33 carriers had an OR of 0.38 (95% CI: 0.18 to 0.79)
(Fig. 3, women, multifactorial adjustment). When pre-
menopausal women, untreated postmenopausal women and
postmenopausal women on HRT were examined separately
(Fig. 5), the protective effect of epsilon32 was statistically
significant in untreated postmenopausal women, while a
nonsignificant trend was observed in the two other smaller
groups of women.
After adjusting for age, male carriers of the epsilon43 and
epsilon44 genotypes versus epsilon33 had ORs for IHD of
1.16 (95% CI: 0.96 to 1.41) and 1.58 (95% CI: 1.01 to
2.45), while the other APOE genotypes did not confer
altered risk (Fig. 4, men, age adjustment). When, in
addition, the analysis adjusted for other known cardiovas-
cular risk factors, including all lipid and lipoproteins except
apoB, male epsilon43 and epsilon44 versus epsilon33 carri-
ers had ORs of 1.35 (95% CI: 1.02 to 1.78) and 1.58 (95%
CI: 0.80 to 3.08) (Fig. 4, men, multifactorial-adjustment).
When the logistic regression analysis adjusted for both
age and apoB levels, the epsilon22 genotype versus epsi-
lon33 had ORs for IHD of 5.1 (95% CI: 1.1 to 23.4) and
Figure 1. Nonfasting lipids and lipoproteins as a function of
apolipoprotein E genotype in women and men from the general
population. Values are adjusted for age in 10 year age groups and
are means 6 95% confidence intervals. ANOVA 5 Kruskal-
Wallis analysis of variance. HDL 5 high density lipoprotein.
Figure 2. Nonfasting lipids and lipoproteins as a function of
apolipoprotein E genotype in premenopausal women, untreated
postmenopausal women and HRT treated postmenopausal
women. Values are adjusted for age in 10 year age groups and are
means 695% confidence intervals. ANOVA 5 Kruskal-Wallis
analysis of variance. HDL 5 high density lipoprotein.
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3.3 (95% CI: 1.2 to 9.2) in women and men, respectively
(Fig. 4, women and men, age, apoB adjustment).
The above-mentioned results of APOE genotype on risk
of IHD were similar when we used: 1) a case-referent study
design, 2) a case-control study design or 3) a pooled
case-control study design (see “Methods,” “Statistical anal-
yses” sections). For simplicity we have chosen only to
present results from the case-referent study.
Interactions of APOE genotype with lipid and nonlipid
cardiovascular risk factors. Of 24 interactions tested, only
one was significant (men, HDL cholesterol, p 5 0.01). In
this case, APOE genotype effects on risk of IHD showed
irregular, rather than consistent, biologically plausible pat-
terns in different strata of HDL cholesterol and, thus,
suggested chance observations.
There was, however, as one should expect because of the
apparent gender specific effects on risk of IHD, a borderline
significant interaction (p 5 0.07) between APOE genotype
and gender in predicting risk of IHD when women and men
were combined.
Fraction of IHD attributed to APOE genotype. Of the
total risk of IHD in the general population, the fraction
attributed to epsilon32 versus epsilon33 in women was 29%
(Table 3). The fractions attributed to epsilon43 and epsi-
lon44 versus epsilon33 in men were 18% and 12%,
equivalent to fractions attributed to hypertension and dia-
betes mellitus combined in men.
DISCUSSION
This study demonstrates that female carriers of the APOE
epsilon32 genotype versus epsilon33 have a 62% (multifac-
torial-adjustment; 95% CI, 21%–81%) reduction in risk of
IHD, while male carriers of epsilon43 and epsilon44 versus
epsilon33 have a 35% (multifactorial adjustment; 95% CI,
2%–78%) and 58% (age adjustment; 95% CI, 1%–145%)
increase in risk, respectively; after multifactorial-
adjustment, the 58% increase in risk in epsilon44 men did
not reach statistical significance (95% CI, 220%–208%).
That APOE genotype may influence risk of IHD differently
in women and men is supported by the borderline statisti-
cally significant interaction term between gender and geno-
type in the logistic regression analysis (p 5 0.07). Of the
total risk of IHD in the population at large, 29% can be
Figure 3. Odds ratio and 95% CI for risk of ischemic heart disease
as a function of tertiles of cholesterol, apoB, HDL cholesterol and
triglycerides. Logistic regression models adjusted for 10 year age
groups. The intermediate and highest levels were compared with
the lowest levels as the reference, except HDL cholesterol where
the lowest and intermediate levels were compared with the highest
levels as the reference. CI 5 confidence interval; HDL 5 high
density lipoprotein. Figure 4. Odds ratio and 95% CI for risk of IHD as a function ofapolipoprotein E genotype relative to the common e33 genotype as
the reference. One logistic regression model adjusted for 10 year
age groups (5 age adjustment), another adjusted for age, choles-
terol, HDL cholesterol, apoAI, triglycerides, lipoprotein(a), body
mass index, hypertension, diabetes mellitus, smoking and, in
addition, menopausal status and use of hormone replacement
therapy for women (5 multifactorial adjustment) and a third
model adjusted for age and levels of apoB (5 age, apoB adjust-
ment). The size of the squares reflects the number of individuals
with each genotype. CI 5 confidence interval.
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attributed to the epsilon32 genotype versus epsilon33 in
women while 18% and 12% can be attributed to epsilon43
and epsilon44 versus epsilon33 in men.
epsilon32 genotype. In this study we find a reduction in
IHD risk associated with the epsilon32 genotype versus
epsilon33 only in women, which is plausible from the
gender specific effects on lipids and lipoproteins; while both
epsilon32 women and men have lower cholesterol and apoB
levels when compared with epsilon33 individuals, epsilon32
women, in addition, have higher HDL cholesterol levels, a
factor that may reduce risk even further; an impact of
APOE alleles on HDL cholesterol levels in women only,
has previously been observed (12). In contrast, epsilon32
versus epsilon33 men in addition have higher nonfasting
plasma triglyceride levels, an effect that may offset the
otherwise beneficial effects of epsilon32 in men. The epsi-
lon2 allele is not totally benign in spite of the very low
cholesterol and apoB levels associated with this allele
because the affinity of the APOE-2 isoform to the LDL-
receptor is very low (1). In the homozygous epsilon22 form,
this leads to accumulation of triglyceride-rich remnant
lipoproteins in plasma and, thus, to a propensity to develop
type III hyperlipoproteinemia (1). The epsilon3 allele of the
epsilon32 genotype can, however, to a large extent compen-
sate for the triglyceride raising effect of the epsilon2 allele,
leaving at least women with an antiatherogenic lipoprotein-
profile.
Since triglycerides appear to be lower in women than in
men (Fig. 1) and lower in premenopausal women and in
postmenopausal women on HRT than in untreated post-
menopausal women (Fig. 2), lipolysis may be better in
women than in men and, specifically, in high estrogen
women. If so, women compared with men would have more
conversion to LDL. But is that bad or good? More LDL
would be disadvantageous, but better remnant removal in
low lipolysis situations, as in men, has the possibility of
LDL receptor downregulation, which could be even worse,
in terms of LDL accumulation. However, normal or high
estrogen levels, as in premenopausal women and in post-
menopausal women on HRT, are not necessary for the IHD
protective effect of the epsilon32 genotype in women; in the
low estrogen group of untreated postmenopausal women
examined separately, the epsilon32 genotype also protected
against IHD.
epsilon43 and epsilon44 genotypes. The present demon-
stration of increased risk of IHD in male carriers of the
epsilon43 and epsilon44 genotypes versus epsilon33 is in
accordance with results from a study including 574 white
men (26) and are, furthermore, indirectly supported by
numerous studies estimating a risk increasing effect of the
epsilon4 allele relative to the epsilon3 allele mainly in men
(1,9,10). Also on this issue, a recent meta-analysis included
181 women and 1,971 men with IHD from nine studies
(27); in spite of the overall impression that the epsilon4
allele increased risk of IHD in both women and men, the
data were not convincing for women. Only four studies
included women, and only one of these showed a significant
OR associated with the epsilon4 allele. Female cases in this
particular study and in two other studies were compared
with a common control group not stratified by gender,
which could mask potential gender specific effects.
Although both women and men with epsilon43 and
epsilon44 versus epsilon33 have higher levels of cholesterol
and apoB, only men with these genotypes have major
increases in triglycerides relative to epsilon33 individuals
(Fig. 1). If epsilon4 women compared with men lipolyze
very low density lipoprotein to LDL better, there would be
Figure 5. Odds ratio and 95% CI for risk of ischemic heart disease
as a function of apolipoprotein E genotype relative to the common
e33 genotype as the reference in premenopausal women (n 5
1,451), untreated postmenopausal women (n 5 2,908) and in
HRT treated postmenopausal women (n 5 689). Logistic regres-
sion models adjusted for 10 year age groups. The size of the
squares reflects the number of individuals with each genotype. The
e22 genotype in premenopausal women and the e22, e42 and e44
genotypes in HRT treated postmenopausal women were too few to
calculate reasonable odds ratios. CI 5 confidence interval; HRT 5
hormone replacement therapy.
Table 3. Fractions of IHD in the General Population
Attributed to APOE Genotypes (Relative to the epsilon33
Genotype) and to Conventional Cardiovascular Risk Factors
Women Men
epsilon22 0.2% 0.8%
epsilon32 29% 20.5%
epsilon42 3% 0.6%
epsilon43 22% 8%
epsilon44 21.0% 2%
Hypertension 18% 4%
Diabetes mellitus 8% 5%
Smoking 15% 23%
Attributable fraction 5 f(R 2 1)/(1 1 f[R 2 1]).
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more LDL in epsilon4 women, but a better and faster
removal of epsilon4 remnants in men might downregulate
LDL receptors severely and lead to higher LDL levels in
men. This could be what is happening, although apoB levels
were similar in women and in men (Fig. 1). If this is the
mechanism for epsilon4 men versus women, and the same
mechanism is operating in the epsilon32 situation, epsi-
lon32 men should also be at an increased risk relative to
epsilon32 women. And they are, although it comes out as
less protective rather than more risk. Alternatively, a sim-
plistic view could be that epsilon43 and epsilon44 genotypes
may increase risk of IHD in men only because triglyceride-
rich lipoproteins may be trapped preferentially to LDL in
the arterial intima to promote accelerated atherosclerosis
(28). In this, as in previous, studies (29), triglycerides
conferred a higher OR for IHD in women than in men.
This may seem paradoxical because the triglyceride raising
epsilon43 and epsilon44 genotypes only raised IHD risk in
men. However, it is important to note that a major
triglyceride raising effect of these genotypes was lacking in
all groups of women (Fig. 1 and 2). It is also possible that
the lack of an association between the epsilon43 and
epsilon44 genotypes versus epsilon33 and IHD in women in
our study is due to lack of power. It should be emphasized
that our evidence for interaction between APOE genotype
and gender on IHD risk only was at the p 5 0.07 level. We
can, therefore, not totally exclude that APOE genotype
affects risk of IHD similarly in women and men.
epsilon22 genotype. It is well known that a subgroup of
carriers of the epsilon22 genotype have the propensity to
develop type III hyperlipoproteinemia, characterized by
severely elevated levels of both triglycerides and cholesterol,
tuberous xanthomas, xanthomas of the palmar creases and
premature IHD (1). In the present population based study,
we could demonstrate that epsilon22 individuals, after
adjustment for low apoB levels, had a three- to five-fold
increase in risk of IHD, probably reflecting an even higher
risk of IHD in a subset of epsilon22 individuals with type
III hyperlipoproteinemia. However, since there were only
two women and five men among patients with IHD with
the epsilon22 genotype, it is also possible that this associa-
tion is due to a few extreme cases.
Attributable fractions. Because 13% of women carry the
epsilon32 genotype, the fraction of the total risk of IHD in
women attributed to this genotype is as much as 29%. In
other words, if all epsilon32 women carried the epsilon33
genotype instead, the total burden of IHD in women would
increase by 9%.
Because 25% and 3% of men carry the epsilon43 and
epsilon44 genotypes, the fraction of the total risk of IHD
attributed to epsilon43 and epsilon44 is 8% and 2%,
respectively. This means that if all male epsilon43 and
epsilon44 individuals carried the epsilon33 genotype in-
stead, the total burden of IHD in men would decrease by
10%. Since this is as much as the fraction attributed to
hypertension and diabetes mellitus combined, it is very
likely that the APOE polymorphism for society as a whole
is the quantitatively most important genetic modulator of
risk of IHD.
Study limitations. Because we genotyped more than
10,000 individuals, we cannot totally exclude misclassifica-
tion of a few APOE genotypes; however, genotype frequen-
cies were in accordance with those predicted by the Hardy-
Weinberg equilibrium and genotyping as well as database
entry was scrutinized by two different researchers. Misclas-
sification of cases is also unlikely, as IHD was diagnosed by
experienced cardiologists and verified by coronary angiog-
raphy, a previous myocardial infarction or a positive exercise
electrocardiography test. Bias due to the investigators’
knowledge of IHD status is unlikely because genotyping
was performed by technical staff who were unaware of
previous knowledge of the effects of the six APOE geno-
types. Potential confounders were taken into account by
adjusting for age and other cardiovascular risk factors in
logistic regression models. Nevertheless, some of our results
could still be chance findings; however, all observations are
in accordance with previous studies and seem plausible from
the effects of APOE genotypes on lipids and lipoproteins.
Finally, linkage disequilibrium with other mutations nearby
is a possible, but very unlikely, confounder; by now it is very
well-established even at the molecular level that differences
in APOE genotype result in different protein isoforms that
interact differently with lipoprotein receptors, thereby caus-
ing different effects on plasma lipids and lipoproteins (1,30–
33).
Measurements of plasma lipids and lipoproteins in the
nonfasting state in subjects sampled from the general
population, but in the fasting state in patients with IHD,
could pose a potential problem, particularly for triglycerides.
This is because it is conventional to measure triglycerides in
the fasting state and because triglycerides increase after a
fatty meal. It could be argued, however, that because most
humans spend more time in the nonfasting state (up to 8 h
after a meal) than in the fasting state (.8 h after a meal),
that the nonfasting state is the most relevant to study, like
we did on effects of APOE on triglyceride levels. Neverthe-
less, because nonfasting triglyceride levels are higher than
fasting levels, this study probably underestimated the role of
triglycerides in predicting IHD.
Conclusion. This study suggested a gender difference of
APOE genotype on risk of IHD; epsilon32 versus epsilon33
is protective in women while epsilon43 and epsilon44 versus
epsilon33 increase the risk in men. The difference between
being an epsilon32 woman and an epsilon43 or epsilon44
man is striking, amounting to up to a four-fold risk
difference. The well known propensity of some epsilon22
individuals to develop hyperlipoproteinemia and, thus, in-
creased risk of IHD could also be demonstrated in this study
in a sample from the general population. These results,
together with previous results, support that APOE geno-
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typing is important in assessing risk of IHD in the individ-
ual. Because the APOE polymorphism is found in white,
black, as well as Asian populations (1), our observations may
apply in many parts of the World.
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